Tower Research Capital (TRC)’s Tango Therapeutics TNGX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$262K Sell
12,537
-7,204
-36% -$100K 0.01% 1410
2025
Q4
$175K Buy
19,741
+13,297
+206% +$115K ﹤0.01% 1544
2025
Q3
$54.1K Sell
6,444
-3,029
-32% -$20.5K ﹤0.01% 2468
2025
Q2
$48.5K Buy
9,473
+2,907
+44% +$7.19K ﹤0.01% 2999
2025
Q1
$8.99K Buy
6,566
+757
+13% +$1.86K ﹤0.01% 3836
2024
Q4
$17.9K Sell
5,809
-8,956
-61% -$41.6K ﹤0.01% 3278
2024
Q3
$114K Sell
14,765
-917
-6% -$8.75K ﹤0.01% 2131
2024
Q2
$135K Buy
15,682
+14,243
+990% +$110K ﹤0.01% 2369
2024
Q1
$11.4K Sell
1,439
-11,770
-89% -$126K ﹤0.01% 3567
2023
Q4
$131K Buy
13,209
+11,761
+812% +$102K ﹤0.01% 2430
2023
Q3
$16.3K Sell
1,448
-1,421
-50% -$8.66K ﹤0.01% 3566
2023
Q2
$9.53K Sell
2,869
-10,454
-78% -$37.6K ﹤0.01% 4265
2023
Q1
$52K Buy
13,323
+10,101
+314% +$58.6K ﹤0.01% 2462
2022
Q4
$23K Sell
3,222
-18
-0.6% -$127 ﹤0.01% 3008
2022
Q3
$12K Buy
3,240
+1,028
+46% +$4.39K ﹤0.01% 4376
2022
Q2
$10K Buy
2,212
+2,112
+2,112% +$12.8K ﹤0.01% 4487
2022
Q1
$1K Buy
+100
New +$867 ﹤0.01% 5861
2021
Q4
Sell
-828
Closed -$11K 6566
2021
Q3
$11K Buy
+828
New +$9.93K ﹤0.01% 4258
2021
Q2
Sell
-17
Closed 5844
2021
Q1
$0 Buy
+17
New +$196 ﹤0.01% 5727

Other funds holding TNGX

Tower Research Capital (TRC)'s TNGX Position: Q1 2026 in Review

Tower Research Capital (TRC) reduced its Tango Therapeutics (TNGX) stake by 36% in Q1 2026, selling an estimated $100K and leaving 12,537 shares worth $262K. The position accounts for 0.01% of the portfolio, ranked #1410.

Tower Research Capital (TRC) first reported a position in TNGX in Q1 2021 and has held it in 19 quarters since. 194 funds tracked by Wall St. Rank hold TNGX as of Q1 2026.

  • Tower Research Capital (TRC) held 12,537 shares of Tango Therapeutics worth $262K as of Q1 2026.
  • Tower Research Capital (TRC) sold 7,204 Tango Therapeutics shares in Q1 2026, an estimated $100K.
  • Tango Therapeutics made up 0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #1410 holding.
  • Tower Research Capital (TRC) first reported a position in Tango Therapeutics in Q1 2021 and has held it in 19 quarters since.
  • 194 funds tracked by Wall St. Rank held Tango Therapeutics as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.